title: The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus.
abstract: OBJECTIVE
  The purpose of this article is to educate nurse practitioners about the role of Toujeo®, insulin glargine U-300 (Gla-300), which is a new option for the treatment of diabetes mellitus.
  
  
  METHODS
  A comprehensive literature search was conducted using MEDLINE with the key terms: insulin glargine 300, Toujeo, Gla-300, and EDITION for clinical trial data. Other resources included package inserts, drug information websites, and the World Health Organization (WHO).
  
  
  CONCLUSIONS
  Gla-300 appears to be a safe and effective option for basal insulin therapy. In clinical trials, it was shown to be equally efficacious as Gla-100 with fewer episodes of hypoglycemia and slightly less weight gain, and subjects receiving Gla-300 required approximately 10 units more basal insulin to obtain the same hemoglobin A1c (HbA1c) as subjects receiving Gla-100.
  
  
  CONCLUSIONS
  This new basal therapy option represents a potential advantage for patients who require higher doses of insulin because of the higher concentration of Gla-300. The lower incidence of hypoglycemia and more predictable pharmacokinetics could offer a significant therapeutic benefit in difficult-to-control patients with diabetes mellitus. The biggest disadvantage of this product is the slightly higher insulin dosage that is required to improve and/or maintain patients' HbA1c.
authors.affiliation: Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi.
authors.forename: Meagan A
authors.initials: MA
authors.lastname: Brown
authors.affiliation: Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi.
authors.forename: Courtney S
authors.initials: CS
authors.lastname: Davis
authors.affiliation: Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi.
authors.forename: Laurie W
authors.initials: LW
authors.lastname: Fleming
authors.affiliation: Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi.
authors.forename: Joshua W
authors.initials: JW
authors.lastname: Fleming
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000069036:Insulin Glargine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D007004:Hypoglycemic Agents; D000069036:Insulin Glargine
keywords: Insulin; diabetes type 1; diabetes type 2; pharmacology; treatment